Aurobindo Pharma shares in focus after USFDA issues 11 observations at Unit III

February 9, 2026
Uncategorized

The inspection, which was carried out between January 27 and February 6, resulted in 11 observations being issued to the plant. Unit III is a formulations manufacturing facility.

Aurobindo Pharma shares in focus after USFDA issues 11 observations at Unit III

Leave a ReplyCancel Reply

Explained — Why shares of PSU Banks rose up to 6% on Monday

US trade breakthrough improves India’s positioning in Asia, says ANZ’s Richard Yetsenga

LSEG FX trading system facing technical issues in India, traders say

Whirlpool of India shares up 5% as Jefferies says Q3 results in-line — Should you buy

Kalyan Jewellers flags alleged market manipulation to SEBI, seeks suspension from F&O segment